COMBODART (dutasteride + tamsulosin), 5-α reductase inhibitor + alpha-blocker

Low clinical benefit for COMBODART as a replacement for separate doses of tamsulosin and dutasteride, if this combination in separate doses has been well tolerated for at least 6 months of treatment.

• COMBODART has Marketing Authorisation in treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) and for the reduction of the risk of acute urinary retention and surgery in patients with moderate to severe BPH symptoms.
• It remains a second-line medicine, prescribed as an alternative to separate doses of tamsulosin and dutasteride, if this combination has been well tolerated for at least 6 months.